PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

PTC Therapeutics Inc.

In a report released today, Eliana Merle from Barclays maintained a Buy rating on PTC Therapeutics, with a price target of $120.00. According to Ti...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTCT	$71.26	0.00%	907.06K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTCT	$71.26	0%	907.06K
3
4
5
6

PTCT

PTCT

Get PTC Therapeutics Inc. Data in Excel

Get PTC Therapeutics Inc. Data in Excel